The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About BBI Life Sciences

Bio Basic Inc., dba BBI Life Sciences (BBI生命科学) (HKG: 1035), is a provider of life science research tools and services including molecular biology kits, biochemicals, synthetic genes and synthetic oligos to customers worldwide. Sangon Biotech (生工生物工程), BBI's main onshore operating entity, is a provider of chemical and biological reagents, DNA synthesis, molecular biology kit, protein, antibody, and laboratory consumables.

BBI Life Sciences Headquarter Location

Shanghai, Shanghai,


+86) 21 800 820 1016

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BBI Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BBI Life Sciences is included in 1 Expert Collection, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Latest BBI Life Sciences News


Mar 13, 2020

0 Message : BBI LIFE SCIENCES CORPORATION Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Offeror or the Company nor is it a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law. BBI LIFE SCIENCES CORPORATION (Stock Code: 1035) PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE Reference is made to the joint announcement issued by LJ Future Ltd. (the "Offeror") and BBI Life Sciences Corporation (the "Company") dated 20 January 2020 (the "Joint Announcement") in relation to, among others, the proposed privatisation of the Company by the Offeror by way of a scheme of arrangement under Section 86 of the Companies Law and the announcements of the Company dated 13 February 2020, 18 Febru- ary 2020, 19 February 2020, 20 February 2020, 21 February 2020, 24 February 2020, 25 February 2020, 26 February 2020, 27 February 2020, 2 March 2020, 3 March 2020, 4 March 2020, 5 March 2020, 6 March 2020 , 9 March 2020 and 11 March 2020 in relation to updates on the number of relevant securities in issue. Capitalised terms used in this announcement shall have the same meanings as those defined in the Joint Announcement unless otherwise stated. This announcement is made by the Company pursuant to Rule 3.8 of the Takeovers Code. UPDATE ON THE NUMBER OF RELEVANT SECURITIES IN ISSUE PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE The Board wishes to announce that on 12 March 2020, a total of 165,040 Shares were allotted and issued as a result of the exercise of 165,040 Options in aggregate, each relating to one Share. The details are as follows: 1 HK$3.23 As at 12 March 2020, the relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company comprised (i) 559,588,123 Shares in issue and (ii) 2,464,700 outstanding Options granted under the Share Option Scheme, each relating to one Share. Save as disclosed, the Company has no other relevant securities as at 12 March 2020. DISCLOSURE OF DEALINGS Associates of the Offeror and the Company (as defined in the Takeovers Code, including shareholders holding 5% or more of the relevant securities (as defined in paragraphs (a) through (e) in Note 4 to Rule 22 of the Take- overs Code) of any of the Offeror and the Company) are hereby reminded to disclose their dealings in any securities of the Company under Rule 22 of the Takeovers Code during the offer period. In accordance with Rule 3.8 of the Takeovers Code, reproduced below is the full text of Note 11 to Rule 22 of the Takeovers Code: "Responsibilities of stockbrokers, banks and other intermediaries Stockbrokers, banks and others who deal in relevant securities on behalf of clients have a general duty to ensure, so far as they are able, that those clients are aware of the disclosure obligations attaching to associates of an offeror or the offeree company and other persons under Rule 22 and that those clients are willing to comply with them. Principal traders and dealers who deal directly with investors should, in appropriate cases, likewise draw attention to the relevant Rules. However, this does not apply when the total value of dealings (excluding stamp duty and commission) in any relevant security undertaken for a client during any 7 day period is less than $1 million. This dispensation does not alter the obligation of principals, associates and other persons themselves to initiate disclosure of their own dealings, whatever total value is involved. Intermediaries are expected to co-operate with the Executive in its dealings enquiries. Therefore, those who deal in relevant securities should appreciate that stockbrokers and other intermediaries will supply the Executive with relevant information as to those dealings, including identities of clients, as part of that co-operation." 2 WARNING Shareholders and potential investors should be aware that the implementation of the Proposal is subject to conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor and/or other professional advisers. On behalf of the Board BBI Life Sciences Corporation Hong Kong, 13 March 2020 As at the date of this announcement, the executive Directors are Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin, the non-executive Director is Mr. Zhou Mi, and the independent non-executive Directors are Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading. 3

  • When was BBI Life Sciences founded?

    BBI Life Sciences was founded in 2013.

  • Where is BBI Life Sciences's headquarters?

    BBI Life Sciences's headquarters is located at Shanghai.

  • What is BBI Life Sciences's latest funding round?

    BBI Life Sciences's latest funding round is IPO.

  • How much did BBI Life Sciences raise?

    BBI Life Sciences raised a total of $10M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.